8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2019

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

Ireland	001-37977	98-1341933
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

Block 10-1
Blanchardstown Corporate Park, Ballycoolin Dublin 15, Ireland	Not Applicable
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: +353 1 485 1200

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares* Ordinary Shares, nominal value $0.01 per share**	AVDL N/A	The Nasdaq Global Market

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) Ordinary Share.

** Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On December 5, 2019, Avadel Pharmaceuticals plc (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials furnished herewith as Exhibit 99.1.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Exhibits

(d) Exhibits

99.1 Corporate presentation of Avadel Pharmaceuticals plc, dated December 5, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 5, 2019	AVADEL PHARMACEUTICALS PLC
	By:	/s/ Phillandas T. Thompson
		Name:	Phillandas T. Thompson
		Title:	Senior Vice President, General Counsel and Corporate Secretary

EX-99.1

Exhibit 99.1

Piper - Jaffray Healthcare Conference December 2019 1 Avadel Pharmaceuticals plc Repositioned: Executing New Strategy

Safe Harbor This presentation may include forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof, identify forward - looking statements, each of which speaks only as of the date the statement is made . Although we believe our forward - looking statements are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks, and, as a result, there can be no assurance that actual results of our research, development and commercialization activities and our results of operations will not differ materially from the results contemplated in such forward - looking statements . These risks include : (a) risks relating to our recent cost - saving actions, including risks that (i) such actions may not result in the amount of cost savings we anticipate ; and (ii) such cost - saving actions may cause us to incur one - time costs in amounts greater than we anticipate ; (b) risks relating to the development of our investigational “FT 218 ” sodium oxybate product, including risks that (i) we may not have adequate capital to complete the development of FT 218 , we may need to obtain additional capital for such purpose, and such additional capital may not be available on attractive terms or at all ; (ii) we could experience delay or failure in completing the Phase 3 REST - ON clinical trial ; iii) we may encounter challenges in the remaining development efforts for FT 218 ; iv) the FDA may determine there are deficiencies in the NDA for FT 218 or may never approve the NDA for FT 218 ; v) FT 218 may not have the therapeutic benefits we anticipate ; vi) the commercial launch of FT 218 could be delayed ; vii) FT 218 may not achieve commercial acceptance ; and viii) other companies may develop competing products that may receive FDA approval before FT 218 ; and (c) the other risks, uncertainties and contingencies described in the Company's filings with the U . S . Securities and Exchange Commission, including our annual report on Form 10 - K for the year ended December 31 , 2018 , and our quarterly reports on Form 10 - Q for the periods ended March 31 , 2019 , June 30 , 2019 , and September 30 , 2019 , in particular disclosures that may be set forth under the captions “Forward - Looking Statements” and “Risk Factors,” including without limitation : our dependence on a small number of products and customers for the majority of our revenues ; the possibility our Bloxiverz ®, Vazculep ® and Akovaz ® products, which are not patent protected, could continue to face substantial and increased competition resulting in a further loss of market share and/or forcing us to further reduce the prices we charge for those products ; the possibility we could fail to successfully complete the research and development for products we are evaluating for potential application to the FDA pursuant to our “unapproved - to - approved” strategy, or that competitors could complete the development of such products and apply for FDA approval of and/or patent protection for such products before us ; the possibility our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do ; and our dependence on key personnel to execute our business plan . You should not place undue reliance on forward - looking statements, which speak only as of the date they are made and are not guarantees of future performance . We do not undertake any obligation to publicly update or revise these forward - looking statements . 2

AT A GLANCE The New Avadel: All the Ingredients for Success 3 FT218 100% $ 72M > $ 55M a differentiated product with high potential enrolled in pivotal Ph3 study REST - ON, single study required for approval cash, funding well into 2021 including completion of REST - ON trial estimated 2019 revenues from legacy hospital portfolio of 3 products – helps fund FT218 18 YEARS Z ERO new chemical entity risk intellectual property protection – until 2037 R IGHT T EAM in place The Z ERO debt due until 2023

THE AVADEL STORY Repositioned, Executing New Strategy. Transformative Next 12 Months Note: 1. Narcolepsy sufferers exhibit excessive daytime sleepiness (EDS) and cataplexy 4 200,000 suffer from narcolepsy 1 in U.S. 2X nightly sodium oxybate 44% non - compliance after 1 year $1.7B sodium oxybate Pivotal Ph3 trial for approval near completion – topline data in Q2 2020 1X nightly sodium oxybate with proprietary Micropump™ controlled release delivery Targeting orphan disease Unsatisfactory standard of care (SOC) Large market Transformation next 12 months Avadel’s differentiated solution

Characteristics of Narcolepsy – Serious Disease with Large Unmet Need ¹Source: GlobalData, June 2018 5 An under - researched and under - diagnosed disease; pathogenesis poorly understood Unmet medical need despite current treatment options Market expected to grow significantly over period to 2027¹ Twice - nightly sodium oxybate is currently the only FDA approved treatment for the symptoms of narcolepsy – excessive daytime sleepiness (EDS) and cataplexy

A New Paradigm of Treatment is Welcomed by Physicians 6 “… I don’t know of another medication where the patient has to wake up in the middle of the night to take it again, this is a serious problem for patients that already have a sleep disorder …” Sleep Specialist KOL, Major Academic Hospital Sleep Center in PA “… The dosing schedule makes it complicated. It’s hard for them to wake up, so they may miss their second dose or take it at the wrong time. It’s also a burden on their spouse or parents or roommates …” Primary Care Physician, Private Clinic in NJ There is high unmet need in patients treated with Xyrem “… [FT218] is what we have been expecting, this is what we want. Patients wouldn’t be so confused about starting therapy… we would almost only use [FT218] over Xyrem …” Sleep Specialist, Academic Hospital Sleep Center in WV “… I would very much prefer [FT218], patients need quality sleep and that’s what [FT218] offers. I would welcome it …” Neurologist, Private Clinic in SC FT218 target product profile strongly resonates with physicians 81% 1 of physicians would prescribe FT218 Note: 1. Data on file - proprietary market research

… And Could be Life Changing for Patients… 7 1X nightly Our Micropump™ delivers one single dose at bedtime “That would be life changing. To not have to get up in the middle of the night, EVERY SINGLE NIGHT. ” – A twice - nightly sodium oxybate patient Life Changing

Leveraging Our Proprietary Micropump™ Technology – Delivering Sodium Oxybate Once Nightly The Advantages • Technology contains thousands of ‘micro particles’ per capsules – each is a miniature delivery system • Microparticulate design can be adapted to each drug’s specific challenges – modify coatings / thickness Delayed delivery of small molecule drugs taken orally 8 200x magnification 20µm 70µm 60µm Inert core Drug layer Controlled release coating 200 - 500 µm diameter The Technology Micro particles Potential to: improve efficacy, reduce toxicity, improve compliance Source: 10 - k pg 89, data on file

0 20 40 60 80 100 0 2 4 6 8 10 Time (h) GHB Concentration (ug/mL) Mean and Standard Error FT218, n=26 Twice - nightly sodium oxybate, n=27 Mean PK Profiles (6g) Investigational Study Clearly Indicated Powerful Potential Advantages of FT218 The Comparison vs. 2X Nightly The Results Single dose Advantage No disruption of sleep Advantage Overall Peak concentration (Cmax) - lower Advantage Overall exposure (AUC) - bioequivalent to SOC Similar Onset time Similar Morning blood levels (C8H) Similar 9

Overview of the Phase 3 Trial, REST - ON Pathway • Abbreviated 505(b)(2) approval process; study conducted under SPA agreement with FDA, requires only 1 pivotal study for approval Study Type • Randomized, double - blind, parallel - group placebo - controlled study with 1:1 randomization to FT218 or placebo in patients with Narcolepsy, either NT1 or NT2 Objectives • Primary objective is to evaluate the efficacy of FT218 • Secondary objective is to evaluate the safety and tolerability of FT218 Primary Endpoints • Maintenance of Wakefulness Test (MWT), Clinical Global Impression (CGI) and number of Cataplexy attacks Dosage / Duration / Participants • Starting dose of 4.5g and titrating up to 9g • 13 - week duration • N = 205 ( completed ) Regulatory Pathway / Study Design 10

Advantage of Legacy Portfolio of Cash Flow Positive Hospital Products AKOVAZ ™ BLOXIVERZ ™ VAZCULEP ™ Commercial sterile injectable products used in the hospital setting 2019 annual revenues of $55M+ supporting development of FT218 Sterile injectable NDA accepted May 2019; PDUFA date of Dec 15, 2019 11 A new 4 TH 3 Estimated Market value of >$30 - 35M

Priorities Going Forward Laser focus on successful completion of pivotal FT218 Ph3 trial Continue to ensure strong liquidity to support FT218 program – includes maximizing cash flow from Hospital products Scale up FT218 manufacturing and complete NDA requirements 1 . 2 . 3 . Advance FT218 “go to market” planning 4 . Build strong credibility with investors by delivering on our commitments 5 . 12

WHAT TO EXPECT: Near - Term Key Milestones Event Date • Completion of patient enrollment (205) Complete • AV001 PDUFA date Dec 15, 2019 • AV001 launch 1H 2020 • Completion of REST - ON study 1H 2020 • REST - ON topline data readout 2Q 2020 1H 2020 13

Piper - Jaffray Healthcare Conference December 2019 14 Avadel Pharmaceuticals plc Repositioned: Executing New Strategy